Of the eighty-four ongoing clinical trials involving PI3K inhibitors for cancer treatment, only three are testing pan-PI3K inhibitors, while the majority focus on isoform-selective inhibitors (Table 2 and Table 3). Here, PIK3CB is linked to cancer.